Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade
Objective: Neoadjuvant chemotherapy followed by radical cystectomy is considered the standard of care for patients with muscle invasive bladder cancer. In the last decade, interest in neoadjuvant chemotherapy has slowly shifted from methotrexate, vinblastine, doxorubicin and cisplatin regime to gemc...
Main Authors: | Sunny Goel, Rahul J. Sinha, Ved Bhaskar, Ruchir Aeron, Ashish Sharma, Vishwajeet Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-07-01
|
Series: | Asian Journal of Urology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388218300584 |
Similar Items
-
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
by: Hyun Hwan Sung, et al.
Published: (2022-03-01) -
Risk factors for failing to complete gemcitabine–cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients
by: Homin Kang, et al.
Published: (2024-05-01) -
Muscle invasive bladder cancer treated with gemcitabine plus cisplatin as neoadjuvant chemotherapy during the second trimester of pregnancy
by: Takeshi Sasaki, et al.
Published: (2025-03-01) -
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
by: Franklin C. Lee, et al.
Published: (2013-01-01) -
Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
by: Daniel Herchenhorn, et al.
Published: (2007-12-01)